Key points from article :
Cyclarity Therapeutics, led by Dr. Matthew O’Connor, is developing UDP-003, a small molecule targeting 7-ketocholesterol to combat atherosclerosis, the leading cause of cardiovascular disease.
UDP-003 enters cells and tissues to remove oxidized cholesterol from plaque buildup in arteries, potentially reducing the risk of heart attacks and strokes.
Manufacturing processes for UDP-003 have been completed, with scalability in mind to ensure affordability for widespread accessibility.
Human clinical trials were initially planned in the UK but have shifted to Australia due to faster regulatory processes post-Brexit.
Phase 1 trials in Australia will focus on safety and potential improvements in arterial disease, paving the way for Phase 2 trials to assess long-term benefits.
Cyclarity is also exploring collaborations for testing UDP-003 in other disease areas and developing new drugs targeting toxic biomolecules associated with aging.
